TABLE 2.
Regression analysis of the relationship between AMB prevalence and AD neuropathological load
| Predictors | Odds Ratio (95% CI) |
P value |
|---|---|---|
| CERAD 0 (indicator) | ||
| CERAD 1 | 1.325 (0.873-2.011) |
0.187 |
| CERAD 2 | 2.433 (1.724-3.433) |
0.001 |
| CERAD 3 | 3.928 (2.897-5.326) |
0.001 |
| BRAAK 0 (indicator) | ||
| BRAAK 1 | 0.548 (0.282-1.065) |
0.076 |
| BRAAK 2 | 0.520 (0.282-0.958) |
0.036 |
| BRAAK 3 | 0.606 (0.330-1.112) |
0.106 |
| BRAAK 4 | 0.868 (0.497-1.518) |
0.620 |
| BRAAK 5 | 1.644 (0.967-2.797) |
0.066 |
| BRAAK 6 | 2.268 (1.349-3.813) |
0.002 |
| LAD (indicator) | ||
| IAD | 2.152 (1.621-2.858) |
0.001 |
| HAD | 3.472 (2.748-4.386) |
0.001 |
Table representing the relationship between AD pathological load, separately and jointly, and AMB prevalence. Predictors referred to presence of neuritic plaques (CERAD score), neurofibrillary pathology (Braak & Braak score) or joint AD pathological load (LAD-HAD). Numerical values within each column represent Odds Ratio (OR) with associated 95% Confidence Interval (95% CI) and p value. The relationship between AD neuropathological load and AMB was assessed in an unadjusted logistic regression model.